US 9,750,789 B2 · Use of matrix metalloproteinase inhibitors to treat tuberculosis

Abstract

The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject.

Claims6

Dependent claims

A method for treating a subject at risk for destruction of lung extracellular matrix comprising administering to the subject a composition comprising an amount of an inhibitor of matrix metalloproteinase-1 (MMP-1) effective to treat the subject, wherein the MMP-1 inhibitor is

a) an antibody which inhibits the binding of a natural ligand of MMP-1 to MMP-1,
b) an antisense molecule which inhibits the expression of MMP-1 in a cell,
c) an RNAi molecule which inhibits the expression of MMP1 in a cell, or
d) cipemastat.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

14/000,134Filed 17 Feb 2012 · us provisional application

Priority

18 Feb 2011

Published

US 2014/0199289 A117 Jul 2014

Granted

5 Sep 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 38/55
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: protease inhibitors
A61K 31/166
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g.…
A61K 31/197
Having an amino group: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA],…
A61K 31/4439
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Use of matrix metalloproteinase inhibitors to treat tuberculosis

Life of this patent

Use of matrix metalloproteinase inhibitors to treat tuberculosis

Life of this patent

Abstract

Claims6